Deal Statistics Quarterly, Q1 2007
We present another installment of our quarterly review of dealmaking-for January-March 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
You may also be interested in...
A year ago at this time, a sale to another company was the last thing on the minds of senior executives at St. Francis Medical, one of the leading companies in dynamic stabilization. But interest by large spine companies put a halt to the company's plans to go public and led to an auction that was eventually won by Kyphon. Kyphon's acquisition of St. Francis Medical was one of the device industry's biggest deals in 2006--and just what everyone was waiting for.
Hedge funds kicked in $110 million in equity bridge financing for the cardiac monitoring company.
In a bold move it says will bolster its late-stage pipeline and provide necessary scale in sales and biologics manufacturing, Schering-Plough Corp. is acquiring the CNS and women's health specialist Organon BioSciences from Dutch conglomerate Akzo Nobel for $14.4 billion. For the acquisition to be a success, SP will have to find value where others have not--specifically in Organon's Phase III schizophrenia treatment asenapine, which was handed back to the company by Pfizer after disappoinging clinical results.